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Abstract
Acute myeloid leukemia (AML) is a disorder with significant molecular and clinical heterogeneity.
Although there have been clear advances in the identification of somatic genetic and epigenetic
alterations present in the malignant cells of patients with AML, translating this knowledge into an
integrated view with an impact on the clinical treatment of AML has been slower to evolve. Recent
clinical advances in the treatment of AML include studies demonstrating the benefit of dose-intense
daunorubicin therapy in induction chemotherapy for patients of any age. We also review use of the
DNA methyltransferase inhibitor azacitidine for treatment of AML in elderly patients as well as a
study of global patterns of DNA methylation in patients with AML. Lastly, we review a recent
assessment of the role of allogeneic hematopoietic stem cell transplantation in AML in first complete
remission.
Introduction and context
Acute myeloid leukemia (AML) is the more common
acute leukemia in adults. Genetic and functional
studies have demonstrated that AML develops as a
result of acquisition of genetic and epigenetic altera-
tions that result in abnormal differentiation and
unlimited self-renewal. Although patients with AML,
with the exception of acute promyelocytic leukemia,
are treated with similar therapies, it has long been
recognized that there is significant biological, clinical,
and genetic heterogeneity in AML. Recent genetic
s t u d i e sh a v ec o n t i n u e dt oe l u cidate molecular altera-
tions in AML with clinical and prognostic significance,
and there is an ever-increasing list of somatic genetic
abnormalities described in AML. In addition to
mutations in MLL, Flt3, NPM1, CEBPa, K/N-Ras, KIT,
and WT1, mutations in the putative epigenetic
modifiers TET2 [1-4] and ASXL1 [ 2 , 5 ]a sw e l la si n
the metabolic enzymes IDH1 and IDH2 [6,7] have
been described in AML in the past year.
Although increasing knowledge of the genetic abnorm-
alities present in AML has continued to improve our
understanding of the biology of this disorder, an
integrated view of the genetic and epigenetic abnormal-
ities found in AML is greatly needed. Even more
challenging will be translating such a comprehensive
characterization into a clinically useful decision
algorithm.
In this review, we summarize the findings from four
recent clinical studies of treatment in AML. The first two
studies focus on optimizing induction chemotherapy
regimens in AML using anthracycline dose-intensifica-
tion. The third study evaluates the role of the DNA
methyltransferase inhibitor azacytidine in the treatment
of elderly patients with AML and a low blast count. The
final study is a discussion of a recent meta-analysis
regarding the use of allogeneic hematopoietic stem cell
transplantation (HSCT) in first remission of AML.
Recent advances
Optimizing induction chemotherapy in AML with
anthracycline dose-intensification
The current standard of care for induction chemother-
apy of AML is 3 days of an anthracycline and 7 days of
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2 continuous intravenous)
[8]. While attempts to increase response rate with the
addition of agents such as thioguanine [9], etoposide
[10], fludarabine [11], and topotecan [11] have failed,
two studies published in the fall of 2009 demonstrated
that intensification of the dose of daunorubicin
improves outcome in de novo AML [12,13].
T h ef i r s ts t u d yb yt h eE a s t e r nC o o p e r a t i v eO n c o l o g y
Group randomized previously untreated AML patients
aged 17-60 years to standard dose (45 mg/m
2)o rh i g h -
dose (90mg/m
2)d a u n o r u b i c i ni nc o m b i n a t i o nw i t h
7 days of cytarabine (100 mg/m
2 continuous infusion)
[12]. Patients in complete remission (CR) were then
offered allogeneic HSCT or high-dose cytarabine, with
or without gemtuzumab ozogamicin, followed by
allogeneic HSCT. Treatment with high-dose daunor-
ubicin resulted in improved CR rate (70.6% versus
57.3%, P < 0.001) and longer overall survival (OS;
median, 23.7 versus 15.7 months).
As the results of this study were published, Löwenberg
et al. [13] simultaneously reported the use of a similar
daunorubicin dose-intensification induction regimen
in elderly AML patients. In this study, newly diag-
nosed AML patients aged 60 years or older (median
age 67) were randomly assigned to receive cytarabine
(200 mg/m
2 continuous intravenous infusion) plus
daunorubicin for 3 days at the conventional dose of
45 mg/m
2 or at the escalated dose of 90 mg/m
2.T h i s
treatment was then followed by a second cycle of
cytarabine at a dose of 1000 mg/m
2 every 12 hours
for 6 days. The elevated dose of daunorubicin led
to an increased CR rate (64% versus 54%, P = 0.002)
b u td i dn o ta f f e c tO Si nt h es t u d yi ng e n e r a l .
However, there was a significant improvement in OS
in patients aged 60-65 years who received the higher-
dose of daunorubicin compared with the conven-
tional dose.
Importantly, in both studies, treatment with high-dose
daunorubicin did not result in significant differences in
hematologic toxicity or adverse events. Moreover,
treatment with high-dose daunorubicin did not pro-
long time to receive consolidation therapy. These
studies suggest that there is a dose-response relation-
ship between anthacycline therapy and AML, and that
anthacycline dose-intensification results in improved
responses without marked increases in attendant
toxicity. Whether dose-intensified daunorubicin is
associated with improved long-term survival remains
to be seen given the short duration of follow-up for
these studies, and more importantly, whether specific
molecularly defined subtypes of AML specifically
benefit from dose-intensified induction regimens.
Use of azacytidine as treatment in AML
Given that most patients with AML are aged 60 years or
older and that treatment with intensive chemotherapy
(such as the dose-intense daunorubicin plus cytarabine
induction described above) is limited to 30-60% of
elderly AML patients [14], there has been great interest in
developing alternative therapeutic strategies for elderly
AML patients. However, clinical trials with low-dose
cytarabine [15], the farnesyl transferase inhibitor tipifar-
nib [16], and gemtuzumab ozogamicin [17] have
demonstrated little or no improvement in overall
survival in elderly patients with AML. Importantly, a
recent phase III randomized trial of the DNA methyl-
transferase inhibitor azacytidine demonstrated an
improvement in survival as a single agent in older AML
patients with 20-30% bone marrow blasts compared
with ‘conventional care regimens’ [18]. In this study,
conventional care regimens were defined as best
supportive care, low-dose cytarabine, or intensive che-
motherapy. Most patients (86%) were considered unfit
for intensive chemotherapy and azacytidine resulted in
an overall survival of 24.5 months compared with 16.0
months for patients receiving conventional care regi-
mens (P < 0.001). Moreover, azacytidine was associated
with fewer days in hospital and higher two-year overall
survival rates.
With further clinical study of epigenetic targeted thera-
pies in AML, it will be important to correlate response to
epigenetic therapies with genome-wide methylation data
before and after treatment. The largest study of the
genome-wide methylation status of AML genomes was
recently published by Figueroa et al. [19]. In this study,
genome-wide promoter DNA methylation profiling was
performed using the HELP assay (HpaII tiny fragment
enrichment by ligation-mediated PCR). In the first part
of the study the authors found that the known
cytogenetic subsets of AML (e.g., t(15;17), inv(16),
t(11q23)) were associated with distinct global DNA
methylation patterns. More interestingly, the authors
then integrated DNA methylation array data with gene-
expression profiling and identified unique subsets of
AML. These specific subsets of AML did not align with
kinase abnormalities described in AML (mutations in
Flt3, N/K-Ras, CBL, KIT, JAK2), suggesting that methyla-
tion and gene-expression changes in AML may be
influenced by alterations other than single activating
kinase mutations. As the molecular characterization of
the epigenetic machinery and landscape of AML
improves, it will be interesting to correlate data from
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tions in epigenetic modifiers and with response to
epigenetic targeted therapy.
Current state of allogeneic HSCT for AML in first remission
The goal of therapy in the treatment of younger patients
with AML is to achieve a cure. While ≥70% of patients
with AML aged <60 years will achieve first CR (CR1), a
substantial number of patients relapse during or after
consolidation therapy [20]. Thus, treatment with allo-
geneicHSCTinyoungpatientswithAMLinCR1hasbeen
frequentlystudied,butuntilrecentlytheuseofallogeneic
HSCT was not well-defined for all risk groups of AML.
Less than 1 year ago, Koreth et al. [21] performed a meta-
analysis of all published data on the use of allogeneic
HSCT versus non-allogeneic HSCT options (autologous
HSCT, consolidation chemotherapy, or both) for
patients with AML aged <60 years in CR1. They used an
intention-to-treat analysis based on donor availability to
capture information from all patients with AML evalu-
ated for up-front allogeneic HSCT with a donor search as
part of a prospective trial. They found that allogeneic
HSCTsignificantlyimprovedrelapse-freesurvivalandOS
for intermediate- and poor-risk AML (based on cytoge-
netic risk) but not in good-risk AML in CR1. Five-year OS
was estimated at 45% and 20% for intermediate- and
poor-risk AML, respectively, with non-allogeneic HSCT
options. This is compared with OS rates of 52% and 31%
for patients with intermediate- and poor-risk AML,
respectively, who underwent allogeneic HSCT.
Previous studies have shown that mutational status is an
important predictor of outcome and treatment response
in AML, including response to allogeneic HSCT. The
landmark study by Schlenk et al. [22] demonstrated the
importance of correlating mutational status of normal
karyotype AML patients with likelihood of attaining
complete remission after chemotherapy and chance of
benefiting from an allogeneic HSCT. In this study, the
mutational status of NPM1, Flt3, CEBPa, MLL, and N-Ras
were assessed in 872 adults aged <60 years with
cytogenetically normal AML. In addition to revealing
the mutational frequency of each of these genes in
normal karyotype AML, the study more importantly
demonstrated that the factors associated with CR in
normal karyotype AML include the genotype of mutant
NPM1 without FLT3 internal tandem duplication (ITD),
the mutant CEBPA genotype, and younger age. More-
over, because 150 individuals in this study underwent
HSCT from an HLA-matched related donor, the authors
were able to identify that the benefit of the transplant
was limited to the subgroup of patients with FLT3 ITD or
the genotype consisting of wild-type NPM1 and CEBPA
without FLT3 ITD.
Implications for clinical practice
The recent clinical studies reviewed here demonstrate
the benefit of high-dose daunorubicin in induction
therapy of AML for patients of any age eligible to
receive intensive chemotherapy [12,13]. Following
successful achievement of complete remission, recent
detailed meta-analyses suggest that allogeneic HSCT is
beneficial for any patient in cytogenetically defined
intermediate- or poor-risk categories [21]. For elderly
AML patients with <30% bone marrow blasts who are
not eligible to receive intensive chemotherapy, treat-
ment with azacitidine appears to improve OS com-
pared with alternative treatments [18]. Given that
many molecular alterations in AML have been demon-
s t r a t e dt oi n f l u e n c er e s p o n se to clinical therapies
[8,12], further efforts to integrate genome-wide mole-
cular alterations with treatment response and outcome
are needed and will inform future analyses of the
cohorts described in these clinical trials. Characteriza-
tion of primary AML samples by the use of high-
throughput genetic, epigenetic, and RNA/microRNA
expression techniques continues to improve, and it will
be important to incorporate molecular analyses into
existing and future clinical trials to delineate genetic
and epigenetic predictors of response and outcome to
specific therapies. With the identification of new
mutated genes in AML since the publication of the
study by Schlenk et al. [22] as well as the ability to
profile the epigenetic state of AML samples, it will be
intriguing to repeat such correlative efforts. In parti-
cular, it will be especially useful to use this biological
information to ascertain the benefit of response to
allogeneic HSCT for those under the age of 60 and the
likelihood of achieving CR for the elderly with AML.
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